In a report released today, Mark Massaro from Canaccord Genuity maintained a Hold rating on Laboratory Corp (LH), with a price target of $170.00. The company’s shares closed last Monday at $164.26.
According to TipRanks.com, Massaro is a top 100 analyst with an average return of 22.2% and a 60.9% success rate. Massaro covers the Healthcare sector, focusing on stocks such as HTG Molecular Diagnostics, Meridian Bioscience Inc, and Castle Biosciences Inc.
Currently, the analyst consensus on Laboratory Corp is a Strong Buy with an average price target of $187.25.
See today’s analyst top recommended stocks >>
Laboratory Corp’s market cap is currently $16.52B and has a P/E ratio of 20.00. The company has a Price to Book ratio of 2.31.
Based on the recent corporate insider activity of 59 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of LH in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Laboratory Corp. of America Holdings is a clinical laboratory company, which engages in the provision of clinical laboratory and end-to-end drug development services. It operates through the LabCorp Diagnostics and Covance Drug Development segments. The LabCorp Diagnostics segment includes core testing as well as genomic and esoteric testing.
